Company’s ultra-sensitive biomarker technology supports latest scientific evidence from study published in Science that Epstein-Barr virus (EBV) increases susceptibility toward multiple sclerosis (MS) ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has successfully ...

The Simoa Disc is the first diagnostic developed using Sony DADC's optical disc manufacturing technology; will be used in Simoa technology to improve testing quality in life science research LEXINGTON ...

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay ...

Quanterix specializes in ultra-sensitive digital immunoassay platforms for early disease detection, potentially transforming disease management. The company's financials show promising growth, with ...

Ultra-sensitive Simoa® HD-X technology powers new findings that detect rapid reduction of plasma P-tau217 from donanemab, Lilly’s investigational antibody therapy for Alzheimer's disease at 12 weeks ...

Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility Quanterix Corporation (NASDAQ: QTRX), a ...

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa ® technology has powered important advances in ongoing clinical ...